Safety Profile of the Use of Iodopovidone for Pleurodesis in Patients with Malignant Pleural Effusion

Background: Iodopovidone is an alternative agent used to promote pleurodesis in patients with malignant pleural effusion (MPE). However, safety is a concern, and many authors still reject its use. Objectives: Our main objective is to describe the occurrence of common and severe adverse events after pleurodesis with two different doses of iodopovidone in patients with MPE. Our secondary objective is to evaluate dose dependency, efficacy, quality of life, and systemic inflammation. Methods: We conducted a double-blind, randomized clinical trial including patients with recurrent MPE. Patients underwent chest tube insertion and were randomized into two groups according to the doses of iodopovidone: group 1 received 1% iodopovidone, and group 2 received 2% iodopovidone. During follow-up, adverse events, inflammatory markers, quality of life, and imaging exams were systematically evaluated and registered. Results: Sixty patients were analyzed (55 females, 5 males, median age 55.9 years). Overall, 227 adverse events possibly related to pleurodesis were registered, including 47 serious adverse Received: May 6, 2015 Accepted after revision: August 18, 2015 Published online: October 7, 2015 José Dias Andrade Neto, MD Thoracic Surgery Division, Hospital Aristides Maltez R Santa Isabela, 100, Torre D, Ap 2801, Engenho Velho da Federação Salvador, BA 40221-225 (Brazil) E-Mail jdnandrade @ yahoo.com.br © 2015 S. Karger AG, Basel 0025–7931/15/0905–0369$39.50/0 www.karger.com/res For editorial comment see p. 355 D ow nl oa de d by : 54 .7 0. 40 .1 1 11 /2 0/ 20 17 9 :4 4: 27 A M